Technical Analysis for POLB - Poolbeg Pharma PLC
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 12.80 | 6.22% | 0.75 |
POLB closed up 6.22 percent on Wednesday, May 1, 2024, on 2.53 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | 1 day ago |
| 5x Volume Pace | 1 day ago |
| 3x Volume Pace | 1 day ago |
| 2x Volume Pace | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a Phase-II ready p38 MAP Kinase inhibitor that reduces harmful inflammation in patients with severe forms of influenza; PredictViral Biomarker Platform, a tool for predicting severe diseases; and vaccine discovery platform, which are techniques used in human challenge models to identify vaccine candidates that drive preferential T-Cell immune responses. The company was formerly known as Orph Pharma Limited and changed its name to Poolbeg Pharma PLC in June 2021. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Disease Medical Specialties Vaccine Health Sciences Medical Research Influenza Vaccination
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Disease Medical Specialties Vaccine Health Sciences Medical Research Influenza Vaccination
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.245 |
| 52 Week Low | 0.1021 |
| Average Volume | 1,824,975 |
| 200-Day Moving Average | 8.63 |
| 50-Day Moving Average | 10.09 |
| 20-Day Moving Average | 10.61 |
| 10-Day Moving Average | 11.27 |
| Average True Range | 0.68 |
| RSI (14) | 73.61 |
| ADX | 31.09 |
| +DI | 37.40 |
| -DI | 9.94 |
| Chandelier Exit (Long, 3 ATRs) | 11.22 |
| Chandelier Exit (Short, 3 ATRs) | 11.68 |
| Upper Bollinger Bands | 12.35 |
| Lower Bollinger Band | 8.87 |
| Percent B (%b) | 1.13 |
| BandWidth | 32.82 |
| MACD Line | 0.60 |
| MACD Signal Line | 0.37 |
| MACD Histogram | 0.2241 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.14 | ||||
| Resistance 3 (R3) | 14.14 | 13.69 | 13.92 | ||
| Resistance 2 (R2) | 13.69 | 13.35 | 13.69 | 13.84 | |
| Resistance 1 (R1) | 13.25 | 13.14 | 13.02 | 13.25 | 13.77 |
| Pivot Point | 12.80 | 12.80 | 12.69 | 12.80 | 12.80 |
| Support 1 (S1) | 12.35 | 12.46 | 12.13 | 12.35 | 11.83 |
| Support 2 (S2) | 11.90 | 12.25 | 11.90 | 11.76 | |
| Support 3 (S3) | 11.46 | 11.90 | 11.68 | ||
| Support 4 (S4) | 11.46 |
